Look back at pharma news in the week to August 28, 2020

30 August 2020

By Barbara Obstoj-Cardwell. Editor

Last week’s notable news included Vertex Pharmaceuticals receiving earlier-than-expected approval in Europe for its Kaftrio plus ivacaftor for multiple sclerosis. Also scoring European approval last week was GlaxoSmithKline’s Blenrep for multiple myeloma. The authorization by US President Donald Trump administration, via the Food and Drug Administration, of emergency use for convalescent plasma to treat COVID-19 patients has raised questions on the agency’s credibility. On the M&A front, Yumanity Therapeutics announced it is merging with Proteostasis, to leverage protein misfolding to advance programs for neurodegenerative diseases, including Yumanity’s Parkinson’s disease candidate YTX-7739.

Kaftrio gets early EU approval, launch will be bumpy given reimbursement processes

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK